

# LOH11CR2A Antibody (N-term) Blocking Peptide

Synthetic peptide Catalog # BP8651a

## **Specification**

## LOH11CR2A Antibody (N-term) Blocking Peptide - Product Information

Primary Accession

000534

# LOH11CR2A Antibody (N-term) Blocking Peptide - Additional Information

**Gene ID 4013** 

#### **Other Names**

von Willebrand factor A domain-containing protein 5A, Breast cancer suppressor candidate 1, BCSC-1, Loss of heterozygosity 11 chromosomal region 2 gene A protein, VWA5A, BCSC1, LOH11CR2A

### **Target/Specificity**

The synthetic peptide sequence used to generate the antibody <a href=/products/AP8651a>AP8651a</a> was selected from the N-term region of human LOH11CR2A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# LOH11CR2A Antibody (N-term) Blocking Peptide - Protein Information

### Name VWA5A

Synonyms BCSC1, LOH11CR2A

### **Function**

May play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.

## **Tissue Location**

Expressed at low level in many tissues. Not expressed in 80% of tumor cell lines tested



# LOH11CR2A Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

## • Blocking Peptides

LOH11CR2A Antibody (N-term) Blocking Peptide - Images

# LOH11CR2A Antibody (N-term) Blocking Peptide - Background

LOH11CR2A may play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.

# LOH11CR2A Antibody (N-term) Blocking Peptide - References

Zhou, Y.Q., et.al., Cancer Sci. 100 (10), 1817-1822 (2009)